These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863 [TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915 [TBL] [Abstract][Full Text] [Related]
30. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance. Mosleh M; Safaroghli-Azar A; Bashash D Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989 [TBL] [Abstract][Full Text] [Related]
31. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286 [TBL] [Abstract][Full Text] [Related]
32. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat. Sears TK; Horbinski CM; Woolard KD J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450 [TBL] [Abstract][Full Text] [Related]
33. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. Sato A; Asano T; Isono M; Ito K; Asano T BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354 [TBL] [Abstract][Full Text] [Related]
34. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559 [TBL] [Abstract][Full Text] [Related]
36. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Wasim L; Chopra M Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904 [TBL] [Abstract][Full Text] [Related]
37. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma. Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658 [TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. Mehrpouri M; Momeny M; Bashash D J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806 [TBL] [Abstract][Full Text] [Related]
39. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446 [TBL] [Abstract][Full Text] [Related]
40. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]